全文获取类型
收费全文 | 2442545篇 |
免费 | 181078篇 |
国内免费 | 3622篇 |
专业分类
耳鼻咽喉 | 33732篇 |
儿科学 | 79372篇 |
妇产科学 | 65164篇 |
基础医学 | 359739篇 |
口腔科学 | 69521篇 |
临床医学 | 218190篇 |
内科学 | 476067篇 |
皮肤病学 | 54672篇 |
神经病学 | 193235篇 |
特种医学 | 91196篇 |
外国民族医学 | 508篇 |
外科学 | 366646篇 |
综合类 | 48321篇 |
现状与发展 | 12篇 |
一般理论 | 891篇 |
预防医学 | 193607篇 |
眼科学 | 56461篇 |
药学 | 181149篇 |
9篇 | |
中国医学 | 4883篇 |
肿瘤学 | 133870篇 |
出版年
2021年 | 19430篇 |
2019年 | 22040篇 |
2018年 | 30621篇 |
2017年 | 22993篇 |
2016年 | 25144篇 |
2015年 | 28507篇 |
2014年 | 40124篇 |
2013年 | 58896篇 |
2012年 | 82423篇 |
2011年 | 87643篇 |
2010年 | 51207篇 |
2009年 | 48115篇 |
2008年 | 80684篇 |
2007年 | 86013篇 |
2006年 | 86256篇 |
2005年 | 84004篇 |
2004年 | 80188篇 |
2003年 | 76718篇 |
2002年 | 72945篇 |
2001年 | 110845篇 |
2000年 | 113298篇 |
1999年 | 94825篇 |
1998年 | 26159篇 |
1997年 | 22631篇 |
1996年 | 22981篇 |
1995年 | 23213篇 |
1994年 | 21369篇 |
1993年 | 20195篇 |
1992年 | 73197篇 |
1991年 | 71375篇 |
1990年 | 69586篇 |
1989年 | 66847篇 |
1988年 | 61390篇 |
1987年 | 60137篇 |
1986年 | 56197篇 |
1985年 | 53942篇 |
1984年 | 39949篇 |
1983年 | 33891篇 |
1982年 | 20106篇 |
1979年 | 36319篇 |
1978年 | 25920篇 |
1977年 | 21411篇 |
1976年 | 20517篇 |
1975年 | 22091篇 |
1974年 | 26432篇 |
1973年 | 25106篇 |
1972年 | 23469篇 |
1971年 | 22281篇 |
1970年 | 20508篇 |
1969年 | 19552篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
51.
52.
53.
54.
55.
56.
57.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献
58.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
59.
60.